GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Cyclacel Pharmaceuticals, Inc. (CYCC) [hlAlert]

Cyclacel Pharmaceuticals, Inc. (Cyclacel) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The Company markets, directly in the United States, Xclair Cream for radiation dermatitis, and Numoisyn Liquid and Numoisyn
Lozenges for xerostomia through its wholly owned subsidiary, ALIGN Pharmaceuticals, LLC (ALIGN). Cyclacel focuses primarily on the development of orally available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors. The Company has been focusing on the cell cycle since its inception. On January 13, 2009, it announced that the Company began treating patients in a Phase II, open label, single arm, multicenter clinical trial of sapacitabine in patients with non-small cell lung cancer (NSCLC) who have had one prior chemotherapy.
.
( Total: 7 Current Stock Recommendations )
Cyclacel Pharmaceuticals, Inc.   (7)
Buy 100%
Related companies
DARA BIOSCIENCES   (2)
Buy 100%
CELSION CORP   (6)
Buy 100%
China Biologic ...   (4)
Buy 100%
ATHERSYS INC   (7)
Buy 100%
ACURA PHARMACEUTICAL   (2)
Buy 100%
China Pharma   (2)
Buy 100%
BioSpecifics ...   (5)
Buy 100%
Derma Sciences, Inc.   (2)
Buy 100%
Tenax Therapeutics ...   (2)
Buy 100%
ARCA BIOPHARMA INC.   (1)
Buy 100%
Filter by Gains:   
  
Rating:
Buy CYCC
down 83.27 %

Rating:
Buy CYCC
down 96.86 %

Rating:
Buy CYCC
down 93.05 %
Cyclacel Pharmaceuticals, Inc. (CYCC) rated Buy by Merriman
Wednesday,  Oct 28, 2009  8:25 AM ET

Rating:
Buy CYCC
down 95.55 %

Rating:
Buy CYCC
down 98.60 %

Rating:
Buy CYCC
down 97.49 %

Rating:
Buy CYCC
down 97.49 %

Rating:
Buy CYCC
down 98.60 %
Cyclacel Pharmaceuticals, Inc. (CYCC) rated Buy
Tuesday,  Nov 27, 2007  9:25 AM ET

Your Recent Stocks
SymbolLastChange
CYCC 0.52 up  1.96 %

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy